Table I.
Comparison of general data, echocardiography results and biochemical markers levels of three groups of patients with pulmonary hypertension due to left heart disease prior to treatment.
| Parameter | Group A (n=20) | Group B (n=20) | Group C (n=20) | F | P-value |
|---|---|---|---|---|---|
| Age (years) | 60.2±3.3 | 59.9±4.2 | 60.8±6.0 | 0.035 | 0.965 |
| Male sex [cases (%)] | 9 (45) | 12 (60) | 10 (50) | 1.262 | 0.291 |
| SBP (mmHg) | 132.2±4.8 | 133.8±9.1 | 128.2±8.0 | 0.039 | 0.962 |
| NBP (mmHg) | 86.8±5.2 | 84.7±5.4 | 85.3±4.0 | 0.053 | 0.948 |
| MAP (mmHg) | 101.9±4.7 | 101.4±6.4 | 99.6±5.1 | 0.034 | 0.967 |
| HR (per min) | 80.6±10.3 | 83.6±8.0 | 81.1±8.9 | 0.042 | 0.959 |
| LAD (mm) | 46.4±4.1 | 46.5±4.8 | 46.2±4.7 | 0.015 | 0.985 |
| LVEDd (mm) | 61.7±5.4 | 62.0±6.6 | 61.9±4.6 | 0.015 | 0.985 |
| LVEF (%) | 39.1±6.2 | 39.6±7.3 | 38.1±6.1 | 0.269 | 0.765 |
| PASP (mmHg) | 62.3±6.9 | 62.1±6.3 | 62.4±7.4 | 0.009 | 0.991 |
| TAPSE (mm) | 15.0±3.6 | 15.1±3.4 | 15.1±2.8 | 0.011 | 0.989 |
| RVFAC (%) | 35.1±4.1 | 35.2±4.2 | 35.0±4.7 | 0.011 | 0.989 |
| NT-proBNP (pg/ml) | 5,153.4±1,821.2 | 5,176.3±1,675.4 | 5,157.3±1,924.5 | 0.001 | 0.999 |
| hsCRP (mg/l) | 6.5±2.9 | 6.3±3.6 | 5.5±2.9 | 0.566 | 0.571 |
Data are presented as the mean ± standard deviation or n (%). LAD, left atrial diameter; LVEDd, left ventricle end diastolic diameter; LVEF, left ventricle ejection fraction; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane systolic excursion; RVFAC, right ventricular fractional area change; NT-proBNP, N-terminal pro-B-type natriuretic peptide; hsCRP, hypersensitive C-reactive protein; HR, heart rate; SBP, systolic blood pressure; MAP, mean arterial pressure; NBP, noninvasive blood pressure.